Skip to main content
Premium Trial:

Request an Annual Quote

John Kolman, Claire Fraser-Ligget, Steven St. Peter

Premium
BioReliance has tapped John Kolman to take over as senior director of research and development. Kolman formerly worked at Invitrogen as principal scientist on the HLA Single Antigen Initiative and lung cancer biomarker programs. He also studied DNA replication initiation at the Salk Institute.
 

 
Claire Fraser-Ligget and Steven St. Peter will not stand for re-election as directors of Helicos Biosciences at the company’s upcoming May stockholder’s meeting, according to a filing with the US Securities and Exchange Commission
 
Until the annual meeting, St. Peter will continue as a member of the Nominating and Corporate Governance Committee and Fraser-Liggett will continue to serve as a member of the Compensation Committee
 
Helicos said that neither of the individuals made their decision due to any disagreement with the company.

Filed under

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.